William Blair Issues Pessimistic Forecast for TMDX Earnings

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities researchers at William Blair reduced their Q1 2025 EPS estimates for TransMedics Group in a research report issued on Monday, December 2nd. William Blair analyst R. Daniels now forecasts that the company will earn $0.34 per share for the quarter, down from their previous forecast of $0.35. The consensus estimate for TransMedics Group’s current full-year earnings is $1.00 per share. William Blair also issued estimates for TransMedics Group’s Q2 2025 earnings at $0.43 EPS.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. TransMedics Group’s quarterly revenue was up 63.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.12) EPS.

TMDX has been the subject of a number of other reports. TD Cowen reduced their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Piper Sandler lowered their price objective on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Oppenheimer reissued an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.80.

TransMedics Group Trading Up 3.0 %

Shares of NASDAQ TMDX opened at $68.26 on Thursday. The business has a fifty day simple moving average of $103.61 and a 200-day simple moving average of $133.93. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 72.62 and a beta of 2.06. TransMedics Group has a 12 month low of $66.10 and a 12 month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $9,457,269.06. This trade represents a 12.27 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,042 shares of company stock worth $3,563,985 over the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Institutional investors have recently bought and sold shares of the stock. Amalgamated Bank increased its holdings in shares of TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after acquiring an additional 70 shares during the last quarter. Harbour Capital Advisors LLC grew its holdings in TransMedics Group by 1.7% during the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock valued at $760,000 after purchasing an additional 81 shares during the last quarter. Signaturefd LLC grew its holdings in TransMedics Group by 26.6% during the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after purchasing an additional 93 shares during the last quarter. Arizona State Retirement System raised its position in shares of TransMedics Group by 2.1% in the second quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock valued at $1,379,000 after purchasing an additional 186 shares during the period. Finally, Venturi Wealth Management LLC lifted its stake in shares of TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after buying an additional 219 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.